Adalta Ltd has released a press release.
BTB funding transferred to AD-214 inhalation program
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from AdAlta
- New pre-clinical data presented at Boston conference
- Corporate overview and IRD Invest 2021 presentation
- $4.0M Non-Dilutive Financing with Victorian Government
- Carina collaboration webinar presentation
- CAR-T collaboration with Carina Biotech
Later from AdAlta
- Second US patent for AD-214
- AGM presentations & first iCAR-T data
- Inhaled AD-214 passes first development milestone
- Voluntary Suspension
- Reinstatement to Quotation
Follow AdAlta into a list and get an email when it puts out news.
Follow AdAlta